| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 | ||
| PCT/EP2015/057224WO2015150476A1 (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| Publication Number | Publication Date |
|---|---|
| SG11201608218QAtrue SG11201608218QA (en) | 2016-10-28 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608218QASG11201608218QA (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| Country | Link |
|---|---|
| US (3) | US9782395B2 (en) |
| EP (2) | EP3125888B1 (en) |
| JP (2) | JP6745726B2 (en) |
| KR (1) | KR102418167B1 (en) |
| CN (1) | CN106470991B (en) |
| AU (1) | AU2015239112C1 (en) |
| CA (1) | CA2943373C (en) |
| CL (1) | CL2016002508A1 (en) |
| CY (2) | CY1120454T1 (en) |
| DK (2) | DK3125888T3 (en) |
| EA (2) | EA202091120A3 (en) |
| ES (2) | ES2872335T3 (en) |
| HR (2) | HRP20180983T1 (en) |
| HU (2) | HUE039555T2 (en) |
| IL (1) | IL248037B (en) |
| LT (2) | LT3388064T (en) |
| MX (1) | MX373234B (en) |
| NZ (1) | NZ725492A (en) |
| PL (2) | PL3125888T3 (en) |
| PT (2) | PT3388064T (en) |
| SG (1) | SG11201608218QA (en) |
| SI (2) | SI3125888T1 (en) |
| WO (1) | WO2015150476A1 (en) |
| ZA (1) | ZA201607286B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US8969581B2 (en)* | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
| WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EA202091120A3 (en)* | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | 2,4-THIAZOLINIDONE DERIVATIVES IN TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
| SI3548026T1 (en)* | 2016-12-01 | 2021-07-30 | Minoryx Therapeutics S.L. | 5-((4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)phenyl)methyl)-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| US11124505B2 (en)* | 2016-12-23 | 2021-09-21 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
| CN112823004A (en)* | 2018-06-06 | 2021-05-18 | 米尼奥尔克斯治疗有限公司 | Use of 5- [ [4- [2- [ 5-acetylpyridin-2-yl ] ethoxy ] benzyl ] -1, 3-thiazolidine-2, 4-dione and salts thereof |
| EP3801515B1 (en) | 2018-06-06 | 2025-04-09 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| WO2019234689A1 (en)* | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| AU2021265345A1 (en) | 2020-04-30 | 2022-12-08 | Minoryx Therapeutics S.L. | Leriglitazone for treating lung inflammation and interstitial lung disease |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| WO2024141951A1 (en) | 2022-12-28 | 2024-07-04 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| WO2024231881A2 (en) | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0579733B1 (en)* | 1991-04-11 | 2001-06-20 | PHARMACIA & UPJOHN COMPANY | Thiazolidinedione derivatives, production and use thereof |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| AU4104593A (en)* | 1992-05-05 | 1993-11-29 | Upjohn Company, The | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| ES2259736T3 (en) | 2001-12-21 | 2006-10-16 | Smithkline Beecham Corporation | DOSAGE REGIME FOR ACTIVATORS OF PPAR-GAMMA-. |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| WO2005016339A1 (en)* | 2003-07-24 | 2005-02-24 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| PL2902026T3 (en)* | 2006-03-16 | 2018-03-30 | Metabolic Solutions Development Company Llc | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| KR20120103711A (en)* | 2009-12-15 | 2012-09-19 | 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| WO2013040419A1 (en)* | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en)* | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| US8969581B2 (en) | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
| WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EA202091120A3 (en)* | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | 2,4-THIAZOLINIDONE DERIVATIVES IN TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210518T1 (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| IL249502B (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
| SI3452465T1 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| HK1216641A1 (en) | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders 123--4- | |
| PL3160464T3 (en) | 6-hydroxybuspirone for use in the treatment of movement disorders | |
| PL3148990T3 (en) | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | |
| HRP20181123T1 (en) | 3,4-diamino-6-chloropyrazine-2-carboxamide compounds for the treatment of enac mediated diseases | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| PT3148990T (en) | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | |
| TH1601002629A (en) | Pyrido[4,3-B]pyrazine-2-carboxamide in the form of nerve-producing substances for Treatment of neurodegenerative disorders | |
| GB201602011D0 (en) | Treating skin disorders | |
| GB201413533D0 (en) | Combination therapy for treating disorders of the vestibular system | |
| GB201416044D0 (en) | The way, Mental Health Therapeutic Technique |